Table 1 MHC class I and class II restricted epitopes.
From: Activated T cell therapy targeting glioblastoma cancer stem cells
Antigen | Sequence | Amino acids | HLA restriction | Reference |
|---|---|---|---|---|
MHC I | ||||
AIM2Intron | RSDSGQQARY | Nonspliced form | A1 | Harada, (2001); Liu, (2004) |
EphA2 883–891 | TLADFDPRV | 883–891 | A2 | Tatsumi, (2003); Pollack, (2014) |
gp100 209–217-2 M | IMDQVPFSV | 209–217 | A2 | Parkhurst, (1996); Akiyama, (2012) |
HER2/neu 773–782 | VMAGVGSPYV | 773–782 | A2 | Nguyen-Hoai, (2012); Phuphanich, (2013) |
IL-13Rα2 345–353 | WLPFGFILI | 345–353 | A2 | Mintz, (2002); Okano, (2002) |
MAGE-A1 161–169 | EADPTGHSY | 161–169 | A1 | Liu, (2004) |
MAGE-A1 278–286 | KVLEYVIKV | 278–286 | A2 | Ottaviani, (2005); Shraibman, (2016) |
NY-ESO-1 157–165 | SLLMWITQC | 157–165 | A2 | Wargo, (2009); Liu, (2018) |
TRP-2 180–188 | SVYDFFVWL | 180–188 | A2 | Liu, (2003); Liu, (2005) |
MHC II | ||||
EphA2663–667 | EAGIMGQFSHHNIIR | 663–677 | DR4 | Tatsumi, (2003) |
gp100576–590 | SLAVVSTQLIMPGQE | 576–590 | DR7 | Kobayashi, (2001) |
HER2/neu36–384 | KIFGSLAFLPESFDGDPA | 369–384 | DPB1*0401 | Liu, (2004); Akiyama, (2012) |
HER2/neu688–703 | RRLLQETELVEPLTPS | 688–703 | DR4 | Disis, (2002); Davis, (2003) |
HER2/neu883–899 | KVPIKWMALESILRRRF | 883–899 | DR1, DR4, DR52, DR53 | Kobayashi, (2000) |
HER2/neu971–984 | ELVSEFSRMARDPQ | 971–984 | DR4 | Knutson, (2001); Davis, (2003) |
NY-ESO-1119–143 | PGVLLKEFTVSGNILTIRLTAADHR | 119–143 | A68 | Matsuzaki, (2008) |
TRP-260–74 | QCTEVRADTRPWSGP | 60–74 | DRB1*0301 | Paschen, (2005) |
TRP-2149–163 | KKRVHPDYVITTQHWL | 149–163 | DRB1*0301 | Osen, (2010) |
